| Literature DB >> 33855293 |
Stephanie Romutis1, Bassem Matta1, Jonathan Ibinson2, John Hileman3, Smiljana Istvanic3, Asif Khalid4.
Abstract
INTRODUCTION: The safety and efficacy of colonic band ligation and auto-amputation (1) as adjunct to endoscopic mucosal resection of large laterally spreading tumors and (2) for polyps not amenable to routine polypectomy due to polyp burden or difficult location remain unknown.Entities:
Keywords: band ligation; colon polyp; colonoscopy; endoscopic mucosal resection; large and laterally spreading tumors
Year: 2021 PMID: 33855293 PMCID: PMC8013638 DOI: 10.1177/26317745211001750
Source DB: PubMed Journal: Ther Adv Gastrointest Endosc ISSN: 2631-7745
Figure 1.EMR-BLA of an LST: (a) an almost hemicircumferential ascending colon LST; (b) flat residual polyp present in EMR bed that was not amenable to snare resection; (c) EMR bed polyp tissue aligned with the banding cap; (d) EMR bed with polyp tissue captured in bands; and (e and f) post-EMR BLA scar with no residual polyp seen 6 months later.
Patient and clinical characteristics including procedure outcomes for the post-EMR-BLA cohort.
| Characteristic | Number/median | Percent/SD (range) |
|---|---|---|
| Gender | ||
| Male | 31 | 96.8% |
| Female | 1 | 3.1% |
| Age (years) | 68 | 9.17 (42–90) |
| Colonoscopy indications | ||
| Anemia | 1 | 2.9% |
| FIT test positive | 2 | 5.9% |
| Known LST | 24 | 70.6% |
| Screening | 1 | 2.9% |
| Surveillance | 6 | 17.6% |
| LST locations: Ileocecal valve | 2 | 5.9% |
| Cecum | 8 | 23.5% |
| Ascending | 5 | 14.7% |
| Transverse | 4 | 11.8% |
| Descending | 6 | 17.6% |
| Sigmoid | 3 | 8.8% |
| Rectum | 6 | 17.6% |
| LST size (mm) | 40 | 10.94 (20–60) |
| Prior endotherapy to LST | ||
| No | 2 | 5.9% |
| Unknown | 7 | 20.6% |
| Yes | 25 | 73.5% |
| Visible residual polyp at the time of EMR-BLA | ||
| No | 4 | 11.8% |
| Yes | 30 | 88.2% |
| Maximum residual size (mm) | 10 | 5.2 (5–20) |
| Number of residual islands | 1.5 | 0.84 (1–4) |
| Number of bands placed | 2 | 1.09 (1–5) |
| LST pathology | ||
| TA | 14 | 41.2% |
| TVA | 11 | 32.4% |
| SSA | 1 | 2.9% |
| TVA-HGD | 3 | 8.8% |
| Invasive carcinomas | ||
| T1b WD-CA | 1 | 2.9% |
| MD-CA | 3 | 8.8% |
| Post-EMR-BLA appearance and pathology | ||
| N/A | 3 | 8.8% |
| Residual polyp | ||
| Pathology-negative | 0 | 0 |
| Pathology-adenoma | 7 | 20.6% |
| Scar | ||
| Pathology-negative | 22 | 63.8% |
| Pathology-adenoma | 1 | 2.9% |
| Scar and ulcer | ||
| Pathology-negative | 0 | 0 |
| Pathology-adenoma | 1 | 2.9% |
| Post-EMR-BLA additional therapy | ||
| APC | 4 | 11.8% |
| Band EMR | 1 | 2.9% |
| BLA | 1 | 2.9% |
| Cold snare/APC | 2 | 5.9% |
| EMR-BLA/APC | 1 | 2.9% |
| None | 21 | 61.8% |
| Surgery | 4 | 11.8% |
| Final pathology | ||
| Negative | 32 | 94.1% |
| T2 MD-CA | 2 | 5.9% |
APC, argon plasma coagulation; BLA, band ligation and auto-amputation; EMR, endoscopic mucosal resection; FIT, fecal immunochemical test; LST, laterally spreading tumors; MD-CA, moderately differentiated adenocarcinoma; SSA, sessile serrated adenoma; TA, tubular adenoma; TVA, tubulovillous adenoma; TVA-HGD, tubulovillous adenoma with high-grade dysplasia; WD-CA, well-differentiated adenocarcinoma.
Figure 2.Images of histopathological changes in EMR-BLA site of T1b rectal adenocarcinoma in surgical specimen: (a, b and c) prominent scar tissue and mild chronic inflammation involving mucosa, submucosa, and superficial layers of muscularis propria; deeper layers of muscularis propria are not involved by scar tissue. No residual adenocarcinoma is seen (4×). (d) Scar tissue involving superficial layers of muscularis propria (10×).
Demographics and clinical characteristics of patients undergoing BLA of polyps not amenable to routine polypectomy.
| Patient | Age (years) | Examination indication | Challenge to endotherapy | No. of BLA procedures | No. of polyps banded | Polyp size (mm) | Total bands placed | Pathology | Follow-up appearance | Follow-up biopsy pathology | Additional endoscopic maneuvers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 66 | Serrated polyposis syndrome | Many confluent polyps | 6 | Many | 5–12 | 67 | SSA | Scars and Polyps | SSA and granulation | Band EMR, APC |
| 2 | 67 | Known polyp/s | Location | 2 | 1 | 20 | 4 | TA[ | Scar | Negative | None |
| 3 | 64 | Screening | Location | 1 | 5 | 10–20 | 5 | SSA | Scar | Negative | None |
| 4 | 55 | Surveillance | Extension into anal canal | 1 | 1 | 10 | 1 | Hyperplastic | N/A | N/A | None |
| 5 | 75 | Known polyp/s | Location | 1 | 1 | 15 | 1 | TVA[ | Scar | Negative | None |
| 6 | 71 | Known polyp/s | Location | 2 | 1 | 20 | 2 | SSA | Scar | Negative | None |
| 7 | 69 | Surveillance | Location | 1 | 12 | Up to 15 | 12 | SSA | Scar | Negative | None |
APC, argon plasma coagulation; BLA, band ligation and auto-amputation; EMR, endoscopic mucosal resection; ICV, Ileocecal valve; SCAD, segmental colitis associated diverticulosis; SSA, sessile serrated adenoma; TA, tubular adenoma; TI, terminal ileum; TVA, tubulovillous adenoma.
Figure 3.BLA of an appendiceal orifice polyp: (a) appendiceal orifice polyp with extension into the appendix; (b) submucosal lift performed pre-EMR; (c) after partial EMR, the ‘intra-appendiceal’ portion of the polyp is suctioned into the cap and a band deployed; and (d) a scar is seen at the BLA site with obliteration of the appendiceal lumen on 6-month follow-up examination.